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Post stroke dysphagia (PSD) is common and associated with poor outcome. The Dysphagia Severity 
Rating Scale (DSRS), which grades how severe dysphagia is based on fluid and diet modification 
and supervision requirements for feeding, is used for clinical research but has limited published 
validation information. Multiple approaches were taken to validate the DSRS, including concurrent- 
and predictive criterion validity, internal consistency, inter- and intra-rater reliability and sensitivity 
to change. This was done using data from four studies involving pharyngeal electrical stimulation 
in acute stroke patients with dysphagia, an individual patient data meta-analysis and unpublished 
studies (NCT03499574, NCT03700853). In addition, consensual- and content validity and the Minimal 
Clinically Important Difference (MCID) were assessed using anonymous surveys sent to UK-based 
Speech and Language Therapists (SLTs). Scores for consensual validity were mostly moderate (62.5–
78%) to high or excellent (89–100%) for most scenarios. All but two assessments of content validity 
were excellent. In concurrent criterion validity assessments, DSRS was most closely associated with 
measures of radiological aspiration (penetration aspiration scale, Spearman rank rs = 0.49, p < 0.001) 
and swallowing (functional oral intake scale, FOIS, rs = −0.96, p < 0.001); weaker but statistically 
significant associations were seen with impairment, disability and dependency. A similar pattern 
of relationships was seen for predictive criterion validity. Internal consistency (Cronbach’s alpha) 
was either “good” or “excellent”. Intra and inter-rater reliability were largely “excellent” (intraclass 
correlation >0.90). DSRS was sensitive to positive change during recovery (medians: 7, 4 and 1 at 
baseline and 2 and 13 weeks respectively) and in response to an intervention, pharyngeal electrical 
stimulation, in a published meta-analysis. The MCID was 1.0 and DSRS and FOIS scores may be 
estimated from each other. The DSRS appears to be a valid tool for grading the severity of swallowing 
impairment in patients with post stroke dysphagia and is appropriate for use in clinical research and 
clinical service delivery.
Post stroke dysphagia (PSD) is common affecting upwards of 40% of patients in the hours to days after ictus, and 
is associated with poor outcome manifest as increased death or dependency, aspiration and pneumonia, and 
malnutrition1. PSD can be identified by screening and clinical bedside assessments, or diagnosed instrumentally 
(videofluoroscopy, VFS; fibreoptic endoscopic evaluation of swallowing, FEES); screening devices are also in 
development2. The severity of aspiration may be quantified using VFS or FEES, and is typically measured using 
the penetration aspiration scale (PAS)3. Similarly, a number of scales exist for grading the severity of clinical 
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dysphagia based on oral intake, such as the functional oral intake scale (FOIS)4, and the dysphagia severity rating 
scale (DSRS)5.
The DSRS is a clinician rated scale that was developed from the dysphagia outcome and severity scale (DOSS)6. 
It grades how severe clinical dysphagia is, by quantifying how much modification is required to fluids and diet, 
as well as level of supervision, for safe oral intake. The DSRS comprises three subscales that are totalled to give 
a score ranging from 0 (best) to 12 (worst). The subscales are five-level ordinal assessments of fluid and dietary 
intake and supervision; each ranges from normal (score 0) to no intake (4) (Table 1).
As with the DOSS, which ranked independence levels according to the Functional Independence Measures 
(FIM) model and was linked to severity7, supervision on the DSRS was also divided into independence levels; 
however, the DSRS does not require a VFS to be performed. To date, the DSRS has been used in several published 
trials of PSD5,8–10. The DSRS is copyright free and open access for research use. The aim of the present study was 
to test and describe the validity of the DSRS in patients with recent stroke. Consensual, content, concurrent cri-
terion, and predictive criterion validity, and internal consistency, inter- and intra-rater reliability, sensitivity to 
change, and minimal clinically important difference were each assessed. Additionally the relationship with the 
FOIS, a validated dysphagia scale4, was examined.
Methods
Approvals, informed consent and ethical approval. This validation study of the DSRS used a mix of 
prospectively-collected data from completed clinical studies and newly collected prospective data; in each case, 
non-attributable anonymised data were analysed. The completed trials each had national ethics approvals and 
patients (or surrogates) had given written informed consent, this covering subsequent data analyses; an individual 
patient data metanalysis has already been published using the three pilot trials. For survey data, the University of 
Nottingham Faculty of Medicine Research Ethics Committee assessed that a full review by the committee was not 
indicated as the requests were distributed via professional networks; participation in the surveys was voluntary 
and anonymous and all data collection was performed in accordance with relevant guidelines and regulations set 
out by the University. Clinical audit data were collected by members of the clinical team and did not need research 
ethics approval. The authors will share a subset of anonymised individual patient trial data with the international 
VISTA Collaboration11.
Validation. Multiple approaches were taken to validate the DSRS including determining consensual, content, 
concurrent criterion and predictive criterion validity12. Additionally, internal consistency, inter- and intra-rater 
reliability, sensitivity to change, and minimal clinically important difference (MCID) were determined.
Data sources. Validation assessments used data from all trials and unpublished studies that are currently 
known to have used the DSRS as an outcome. These included raw data from published trials of pharyngeal elec-
trical stimulation (PES)5,8–10, an individual patient data meta-analysis of the first three of these PES trials13, and 
unpublished studies (NCT03499574, NCT03700853). All studies involved patients with acute and/or sub-acute 
stroke.
Consensual and content validity were assessed from an anonymous survey sent to 20 UK-based Speech and 
Language Therapist (SLT) experts with experience of working with adults with acquired dysphagia. Relevant 
additional information was provided to the respondents regarding the background and purpose of the scale, and 
what patient group it was designed for. Similarly, to establish the MCID, an anonymous survey was distributed to 
a number of UK professional networks of SLTs with experience of working with adults with acquired dysphagia.
Consensual validity. This is the validity of a test determined by its general acceptance in the commu-
nity of users, or by the number of users who judge it to be valid. Consensual validity was assessed by asking 
respondents to rate 5 scenarios using the DSRS, as recently used in validation of the International Dysphagia Diet 
Standardisation Initiative (IDDSI) functional diet scale14. Scenarios required respondents to rate recommenda-
tions of full amounts of oral intake, minimal and consistent oral trials, liquid only diets and accompanying levels 
of supervision. Respondents were asked to provide additional comments at the end of the survey. Excellent or 
good agreement were considered acceptable.
content validity. This refers to the extent that a test includes all aspects of its construct, including relevance 
and comprehensiveness. Relevance was assessed using the content validity index (CVI), an indicator of inter-rater 
agreement that asks experts to appraise how relevant items are;15,16 it is particularly appropriate to use on instru-
ments that have scales with multiple items15,16. Experts considered the relevancy (score 1 for not relevant, to 4 
Score Fluids Score Diet Score Supervision
4 No oral fluids 4 Non oral feeding 4 No oral feeding
3 Pudding consistency 3 Puree 3 Therapeutic feeding (SALT/trained staff)
2 Custard consistency 2 Soft, moist diet 2 Feeding by third party (untrained)
1 Syrup consistency 1 Selected textures 1 Eating with supervision
0 Normal fluids 0 Normal 0 Eating independently
Table 1. Dysphagia Severity Rating Scale (DSRS). NB Mashed diet texture recommendations will be rated as 
for ‘puree’ diet texture.
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for highly relevant) for each item on each sub-scale. Item (I-CVI) and scale (S-CVI) level indices were calculated 
according to Polit15,16. In parallel, the subscales were assessed for comprehensiveness and whether their wording 
was clear.
Concurrent criterion validity. This demonstrates how well DSRS correlates with other stroke-related clin-
ical and radiological measures taken at the same timepoint. These included radiological aspiration (penetration 
aspiration score, PAS by VFS3), swallowing (Toronto bedside swallowing screening test [TOR-BSST]17, using the 
sum of the 14 components rather than just the dichotomous pass/fail score; and FOIS4), neurological impair-
ment (National Institutes of Health stroke scale, NIHSS), disability (Barthel index, BI18), dependency (modified 
Rankin scale, mRS18), and quality of life (EuroQoL 5-dimension 3-level, EQ-5D-3L; EuroQoL visual analogue 
scale, EQ-VAS19). Associations were performed at all available timepoints, typically at baseline, and on and after 
treatment, using Spearman’s correlation coefficient.
predictive criterion validity. This demonstrates how well DSRS at baseline correlates with the 
stroke-related clinical and radiological measures assessed at a later timepoint; the measures are those as identified 
immediately above for concurrent criterion validity, and analysed using Spearman’s correlation coefficient.
internal consistency. This assesses how well the components of the scale relate to each other and is a meas-
ure of scale reliability. The interrelation between scores from the three subscales were assessed using Cronbach’s 
alpha20. Data sources were the STEPS, Vasant and PHAST-TRAC trials, and anonymised clinical audit data from 
a stroke ward as determined by a Speech and Language Therapist (JB) and Research Practitioner (AH).
Inter/intra-rater reliability. These are the degree of agreement among raters, and among repeated meas-
urements by one rater, respectively. Inter-rater and intra-rater reliability was performed by JB and AH using the 
same audit data as used for internal consistency. Both measures of reliability were assessed using the inter-class 
correlation (ICC).
Sensitivity to change. This is also known as responsiveness21 and refers to how well an instrument identi-
fies longitudinal changes, in a proportionate manner16. Changes in the DSRS during the rehabilitation phase after 
stroke, i.e., from study baseline to final follow-up, were assessed using data from the STEPS trial.
Minimal clinically important difference (MCID). The MCID is the minimum difference in a score that 
is considered valuable and changes patient management22. MCID was assessed in three different ways through 
assessment of statistical distribution (both half standard deviation and standard error of mean), anchor, and 
consensus through a survey23–25. Data for analysis of statistical distribution and anchor methods came from 
the STEPS trial and an individual patient data meta-analysis of three pilot trials of PES9,13. The survey involved 
UK-based SLTs. The survey was sent to a number of professional networks and it was up to the discretion of the 
network administrators whether the survey was forwarded.
Relationship between DSRS and FOIS. The DSRS and FOIS measure overlapping aspects of clinical 
dysphagia although they have an opposite direction of severity. Their relationship and interconversion were deter-
mined through mapping equivalent levels and using data from studies that measured both in parallel. Where a 
range of values was estimated the median of these is given.
Statistical analyses. In addition to the specific analyses detailed above, standard approaches were used to 
present results as number (%), median [interquartile range, IQR] or mean (standard deviation, SD).
Results
Trial individual patient data. Four trials of pharyngeal electrical stimulation after stroke have been per-
formed where DSRS was recorded: Jayasekeran, Vasant, STEPS and PHAST-TRAC5,8–10. Data on DSRS and other 
clinical and radiological measures were available at baseline and variously at days 2, 14, 30 and 90. The clinical 
characteristics of patients by baseline DSRS are shown for these studies (Supplementary Table I), note for all sup-
plementary tables, please see online resource. The mean age was 71 (SD 12) years with 109 (38%) female, mean 
onset to randomisation of 21 (SD 17) days; the most common clinical syndrome was partial-anterior circulation, 
92 (43%) and just 3 (1%) patients had a posterior syndrome; 211 (85%) participants had an ischaemic stroke and 
38 (15%) an intracerebral haemorrhage. A ceiling effect was noted at baseline with 139 (48%) patients having a 
maximum DSRS score of 12. Increasing dysphagia impairment, assessed using the DSRS, was significantly associ-
ated with time from onset to randomisation, worse neurological deficit (NIHSS), stroke type, dependency (mod-
ified Rankin scale), disability (Barthel index), swallow screening (component score on TOR-BSST), radiological 
aspiration (PAS) and non-oral feeding state (Supplementary Table I).
Consensual validity. As Speech and Language Therapists (SLTs) are the primary clinicians who treat dys-
phagia in the UK, anonymous surveys were sent to 20 invited UK based SLT clinicians. Between eight and ten 
respondents rated each scenario. Seventy percent of respondents had 10+ years’ experience. The areas of expertise 
of the respondents was: stroke (5), head and neck (2), dementia (1), other (2). Consensus was excellent (100%) 
for recommendations of full oral intake; moderate (78%) to low (56%) for minimal oral trials of liquids (e.g. 5 
sips) and solids (e.g. 5 tsps.) respectively, and high (89%) and moderate (78%) for consistent oral trials of liquids 
(e.g. 100 ml) and solids (e.g. half portions of diet) respectively (Supplementary Table II). Consensus was excellent 
for scoring liquid-only  fluids (100%) but not the accompanying diet component of this scenario (63%) which 
means this component, overall, had a moderate consensus. Supervision scores were high (80–100%) for full oral 
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intake, high (89%) for minimal oral trials and moderate (67%) for consistent oral trials (Supplementary Table II). 
Respondents’ comments requested clarification on how to score consistent amounts of oral trials and liquid diets.
content validity. Ten of the 20 invited UK-based SLTs responded to the anonymous survey. This is an 
acceptable number of expert views for undertaking content validation of an instrument15. All but two compo-
nents of the DSRS sub-scales had “excellent” relevance (I-CVI > 0.90); “pudding consistency” was good and 
“selected textures” was fair (Table 2). At a scale level, both the fluid and food scale achieved an S-CVI/Ave rating 
of 0.84 (good) and the supervision scale a rating of 0.96 (excellent). Expert feedback regarding wording and com-
prehensiveness are given in Supplementary Table III; many of these related to the lack of mention of IDDSI26 in 
the DSRS definitions, a point we address in the Discussion.
Concurrent criterion validity. Data were available for all four trials5,8–10. In the largest (STEPS), DSRS at 
baseline and weeks 2 and 13 was associated significantly and in appropriate directions with measures, at the same 
time points of aspiration (PAS using VFS), swallowing (TOR-BSST), disability (Barthel index) and dependency 
(modified Rankin scale) (Table 3). At 2 weeks post randomisation, DSRS was also associated with impairment 
(NIHSS). DSRS was not related to quality of life measures at 13 weeks post randomisation. The three sub-scale 
components of the DSRS (fluids, diet and supervision) were also each associated significantly with aspiration at all 
three time points. Similar magnitudes of associations were seen in the smaller studies of Jayasekeran5 and Vasant8 
(Table 3) although associations did not always reach significance in these studies8. Overall, associations were 
stronger between DSRS and measures of swallowing and aspiration then with global measures of impairment 
(NIHSS), disability (BI) and dependency (mRS).
DSRS was strongly negatively correlated with FOIS at day 2 and week 13 in the PHAST-TRAC trial (Table 3); 
the association could not be performed at baseline since all participants had a DSRS of 12/FOIS of 1 as part of the 
trial’s inclusion criteria27.
predictive criterion validity. Using data from the STEPS trial, baseline DSRS was associated with radiolog-
ical aspiration (VFS PAS) at 2 and 13 weeks; and swallowing (TOR-BSST), disability (BI) and dependency (mRS) 
at 2 weeks (Table 4). There was no association with impairment (NIHSS), or quality of life (EQ-5D-3L, EQ-VAS). 
The three DSRS sub-scale components (fluids, diet and supervision) at baseline were also each associated signifi-
cantly with radiological aspiration at 2 and 13 weeks.
Associations between baseline DSRS and post-treatment measures in the trials of Jayasekeran and Vasant were 
not statistically significant. It was not possible to assess the relationship between baseline DSRS and post treat-
ment FOIS in the PHAST-TRAC trial since all participants had a baseline DSRS score of 1227.
internal consistency. The interrelation between the scores from the three subscales, at various timepoints, 
were assessed using Cronbach’s alpha20 using data from STEPS, Vasant and PHAST-TRAC trials8–10. Internal con-
sistency was “Good” at baseline, varied between “Good” and “Excellent” over the first two weeks, and “Excellent” 
at 12 weeks (Supplementary Table IV). Similarly, audit of clinical data by JB and AH revealed “Excellent” consist-
ency between the subscales (Supplementary Table V).
Item
Rating 3 or 4 (N 
of 3, 4) I-CVI Rating S-CVI Rating
Fluids sub-scale
No oral fluids 9 (1, 8) 0.90 Excellent 0.84 Good
Pudding consistency 7 (3, 4) 0.70 Good
Custard consistency 8 (1, 7) 0.80 Excellent
Syrup consistency 8 (1, 7) 0.80 Excellent
Normal fluids 10 (2, 8) 1.00 Excellent
Diet sub-scale
Non oral feeding 9 (1, 8) 0.90 Excellent 0.84 Good
Puree (mashed) 10 (0, 10) 1.00 Excellent
Soft, moist diet 9 (1, 8) 0.90 Excellent
Selected textures 5 (3, 2) 0.50 Fair
Normal diet 9 (0, 9) 0.90 Excellent
Supervision
No oral feeding 9 (2, 7) 0.90 Excellent 0.96 Excellent
Therapeutic feeding 10 (0, 10) 1.00 Excellent
Feeding by third party 9 (0, 9) 0.90 Excellent
Eating with supervision 10 (0, 10) 1.00 Excellent
Eating independently 10 (0, 10) 1.00 Excellent
Table 2. Content validity of DSRS sub-scales assessed by 10 UK speech and language therapists. Interpretation 
of I-CVI: Excellent >0.78; Good > 0.60–0.78; Fair >0.40- < 0.60 15. Interpretation of S-CVI: Excellent >0.90; 
Good >0.80- < 0.9015. S-CVI is average of I-CVI in sub-scale.






(weeks) N Median (IQR) rs P
STEPS9
Total score
DSRS Dysphagia 0 to 12 0 154 7 (8) — —
2 131 4 (5) — —
13 106 1 (3) — —
VFS-PAS Aspiration 1 to 8 0 154 4.71 (3.66) 0.488 <0.001
2 126 3.27 (3) 0.387 <0.001
13 95 2.29 (2.93) 0.398 <0.001
TOR-BSST Swallowing 0 to 14 0 154 1 (3) −0.167 0.038
2 127 2 (10) −0.459 <0.001
13 103 6 (13) −0.520 <0.001
NIHSS Impairment 0 to 42 0 150 9 (10) 0.020 0.81
2 131 8 (10) 0.301 <0.001
13 106 5 (8) 0.117 0.23
BI Disability 0 to 100 0 151 20 (40) −0.279 0.001
2 131 25 (60) −0.517 <0.001
13 106 65 (65) −0.407 <0.001
mRS Dependency 0 to 5 0 151 4 (1) 0.179 0.028
2 131 4 (2) 0.382 <0.001
13 106 4 (2) 0.279 0.004
EQ-VAS QoL 0 to 100 13 87 58 (35) −0.149 0.17
EQ-5D-3L QoL −0.5 to 1.0 13 95 −0.04 (0.489) −0.109 0.29
Fluids
VFS-PAS Aspiration 1 to 8 0 154 4.71 (3.66) 0.498 <0.001
2 126 3.27 (3) 0.374 <0.001
13 95 2.29 (2.93) 0.362 <0.001
Diet
0 154 4.71 (3.66) 0.402 <0.001
2 126 3.27 (3) 0.416 <0.001
13 95 2.29 (2.93) 0.371 <0.001
Supervision
0 154 4.71 (3.66) 0.417 <0.001
2 126 3.27 (3) 0.236 0.008
13 95 2.29 (2.93) 0.343 0.001
Jayasekeran5
Total score
DSRS Dysphagia 0 to 12 0 28 5.5 (11) — —
2 28 2.5 (5) — —
VFS-PAS Aspiration 1 to 8 0 28 4.5 (3) 0.345 0.073
2 28 4 (3) 0.146 0.46
BI Disability 0 to 20 0 28 6 (4) −0.340 0.077
2 28 14 (7) −0.273 0.16
Vasant8
Total score
DSRS Dysphagia 0 to 12 0 36 8 (8) — —
2 34 3 (8) — —
13 32 1 (3) — —
VFS-PAS Aspiration 1 to 8 0 18 3.50 (4) 0.551 0.018
2 15 3 (2) 0.537 0.039
13 10 1 (2) 0.159 0.66
NIHSS Impairment 0 to 42 0 36 11.50 (11) 0.142 0.41
2 33 6 (7) 0.378 0.030
13 26 4 (5) 0.301 0.14
BI Disability 0 to 100 0 36 21.50 (39) −0.017 0.92
2 34 37.50 (50) −0.400 0.019
13 27 65 (58) −0.258 0.20
mRS Dependency 0 to 5 0 35 4 (1) −0.030 0.86
2 33 3 (2) 0.359 0.040
13 27 2 (2) 0.311 0.11
PHAST-TRAC10
Continued
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Inter/intra-rater reliability. DSRS was scored in 31–58 hospitalised stroke patients by JB and AH. The 
inter-rater reliability was “Excellent” for DSRS with intra-class correlation (ICC) = 0.955 (95% confidence inter-
vals 0.925, 0.973); similarly, the intra-rater reliability was “Excellent” (Table 5). Assessments within the subscale 





(weeks) N Median (IQR) rs P
Total score
DSRS Dysphagia 0 to 12 0 69 12 (0) — —
0.3 60 10.5 (2.5) — —
13 52 5.1 (5.2) — —
FOIS Dysphagia 1 to 7 0 69 1 (0) ND ND
0.3 60 1.8 (1.3) −0.955 <0.001
13 52 4.3 (2.6) −0.978 <0.001
Table 3. Concurrent criterion validity - Relationships between DSRS and clinical and radiological assessments 
at a variety of timepoints in trials of pharyngeal electrical stimulation. (Spearman’s rank correlation coefficient). 
*DSRS range is 0–12 for total score, and 0–4 for subscales. BI: Barthel index; DSRS: dysphagia severity 
Rating scale; EQ-5D-3L/HUS: EuroQoL-5 dimension-3 level as health utility scale; EQ-VAS: EuroQoL-visual 
analogue scale; FOIS: functional oral intake scale; mRS: modified Rankin scale; NIHSS: National Institutes of 
Health Stroke Scale; PAS: penetration aspiration scale3; Richmond agitation and sedation scale (RASS)29; VFS: 
videofluoroscopy. ND: Not done - all participants had DSRS = 12 and FOIS = 1 at baseline27.




(weeks) N Median (IQR) rs P
STEPS9
Total score VFS-PAS Aspiration 1 to 8 2 126 3.27 (3) 0.461 <0.001
13 95 2.29 (2.93) 0.419 <0.001
TOR-BSST Swallowing 0 to 14 2 127 2 (10) −0.252 0.004
13 103 6 (13) −0.131 0.19
NIHSS Impairment 0 to 42 2 132 8 (10) 0.094 0.28
13 106 5 (8) −0.010 0.92
BI Disability 0 to 100 2 132 25 (59) −0.281 0.001
13 107 65 (65) −0.176 0.070
mRS Dependency 0 to 5 2 132 4 (2) 0.177 0.042
13 110 4 (2) 0.048 0.62
EQ-5D-3L QoL −0.5 to 1.0 13 95 −0.04 (0.489) −0.075 0.47
EQ-VAS QoL 0 to 100 13 87 58 (35) 0.070 0.52
Fluids† VFS-PAS Aspiration 1 to 8 2 126 3.27 (3) 0.445 <0.001
13 95 2.29 (2.93) 0.394 <0.001
Diet† 2 126 3.27 (3) 0.365 <0.001
13 95 2.29 (2.93) 0.351 <0.001
Supervision† 2 126 3.27 (3) 0.388 0.001
13 95 2.29 (2.93) 0.342 0.001
Jayasekeran5
Total score VFS-PAS Aspiration 1 to 8 2 28 4 (3) −0.220 0.26
BI Disability 0 to 20 2 28 14 (7) −0.303 0.12
Vasant8
Total score VFS-PAS Aspiration 1 to 8 2 16 3 (4) −0.058 0.83
13 11 1 (2) −0.169 0.62
NIHSS Disability 0 to 42 2 33 6 (7) 0.245 0.17
13 27 4 (4) 0.104 0.61
BI Disability 0 to 100 2 34 38 (50) −0.242 0.17
13 28 65 (56) −0.113 0.57
mRS Dependency 0 to 5 2 33 3 (2) 0.098 0.59
13 28 2 (2) 0.099 0.62
Table 4. Predictive criterion validity - Relationships between DSRS at baseline with clinical and radiological 
assessments on or after treatment in trials of pharyngeal electrical stimulation. (Spearman’s rank correlation 
coefficient). *DSRS range: 0–12 for total score; 0–4 for subscales. †Associations between post-treatment DSRS 
and outcome measures at subsequent timepoints. BI: Barthel index; DSRS: dysphagia severity Rating scale; EQ-
5D-3L/HUS: EuroQoL-5 dimension-3 level as health utility scale; EQ-VAS: EuroQoL-visual analogue scale; 
FOIS: functional oral intake scale; mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke 
Scale; PAS: penetration aspiration scale; VFS: videofluoroscopy.
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Sensitivity to change. DSRS scores were sensitive to spontaneous recovery for patients with acute/subacute 
PSD, declining during follow-up in STEPS with modal values of 12, 3 and 0 at weeks 0 (baseline), 2 and 13 respec-
tively (Fig. 1). Similarly, the median (7, 4, 1) and mean (7.6, 4.9, 2.7) values declined at the same timepoints. As 
with VFS-PAS, DSRS was sensitive to treatment with pharyngeal electrical stimulation in a meta-analysis of three 
pilot trials being 1.7 points lower (p = 0.040) in the PES group as compared with the control group13. In contrast, 
the STEPS trial was neutral for the effect of PES on VFS-PAS and there was no difference in DSRS scores between 
treatment groups9.
Minimal clinically important difference (MCID). The survey was based on 84 responses from UK based 
SLTs, the majority of whom had more than 10 years’ experience. It was not possible to estimate the number that 
received the survey therefore response rate could not be calculated. MCID varied between 0.3 and 2.5 with all 
three approaches - statistical, anchor and survey - identifying a MCID of 1.0 as being important (Supplementary 
Table VI).
Relationship between DSRS and FOIS. FOIS could be extrapolated from DSRS scores (Supplementary 
Table VII); however, some combinations of DSRS subscale scores are incongruent from a clinical perspective (e.g. 
use of thickened fluids when taking a normal diet) and so these have no equivalent FOIS value. Conversely, DSRS 
could be estimated from FOIS although in most cases it was not possible to determine subscale results since the 
subscales of supervision and fluids above level 3 are not scored on the FOIS (Supplementary Table VIII).
The PHAST-TRAC trial recorded both DSRS and FOIS at multiple post-randomisation timepoints (days 2, 4, 
6, 8, 10, 30 and 90)10. The frequency of paired scorings is shown in Supplementary Table IX. The inverse nature of 
DSRS and FOIS is noted and percentages match the estimated equivalents in Supplementary Tables VII and VIII.
Discussion
This comprehensive assessment of the DSRS suggests that it is a valid tool for grading dysphagia severity (based 
on oral intake and supervision requirements) in patients with post-stroke dysphagia. Using data from four ran-
domised controlled trials and 2 surveys, the DSRS was found to exhibit consensual validity, content validity, 
concurrent criterion validity, predictive criterion validity and internal consistency. Once operationalisation of 
scoring for certain feeding scenarios was undertaken, inter- and intra-rater reliability were “excellent” when used 
in a clinical audit, and the minimal clinically important difference approximated to 1 unit irrespective of the 
method of estimation. The DSRS was sensitive to change during the natural resolution of dysphagia seen through 
the sub-acute and rehabilitation phases after stroke, and in response to treatment with pharyngeal electrical stim-
ulation in some trials. The intrinsic relationship between DSRS and FOIS allowed these two dysphagia scales to 
be mapped to each other.
The main strength of this study is the large number and variety of detailed validations performed. We also pro-
vide data on minimal clinical important difference and a means for interconverting the DSRS and FOIS. Second, 
much data came from two phase III trials (STEPS, PHAST-TRAC) rather than just a number of smaller studies. 
Third, patients with a range of post-stroke severity were included in these validations, with mild-to-moderate 
patients coming from three trials5,8,9 and more severe ones from one10. Fourth, a large amount of clinical and 
radiological outcome data were available. This showed that overall, the DSRS was highly correlated with another 
clinical measure of dysphagia severity (FOIS). Measures of aspiration (VFS-PAS) and swallowing (TOR-BSST) 
Comparison Scale ICC Interpretation
Inter-rater
1 (n = 58) DSRS 0.955 (0.925, 0.973) Excellent
Fluids 0.837 (0.740, 0.900) Good
Diet 0.985 (0.974, 0.991) Excellent
Supervision 0.952 (0.921, 0.971) Excellent
Inter-rater
2 (n = 31) DSRS 0.929 (0.859, 0.965) Excellent
Fluids 0.721 (0.501, 0.855) Moderate
Diet 0.982 (0.965, 0.992) Excellent
Supervision 0.958 (0.915, 0.979) Excellent
Intra-rater
1 (n = 41) DSRS 1.00 (1.00, 1.00) Excellent
Fluids 1.00 (1.00, 1.00) Excellent
Diet 1.00 (1.00, 1.00) Excellent
Supervision 1.00 (1.00, 1.00) Excellent
Intra-rater
2 (n = 31) DSRS 1.00 (1.00, 1.00) Excellent
Fluids 1.00 (1.00, 1.00) Excellent
Diet 1.00 (1.00, 1.00) Excellent
Supervision 1.00 (1.00, 1.00) Excellent
Table 5. Intra- and inter-rater reliability for DSRS and subscales assessed using the intra-class correlation. Each 
rater scored data on two occasions separated by a month. Interpretation: Excellent >0.90; good >0.75–0.90; 
moderate 0.50–0.75; poor <0.50.
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were more strongly correlated than global measures of impairment, disability, and dependency (although these 
still showed some significant correlations) and (perhaps surprisingly) the DSRS was not correlated with a generic 
health status measure of quality of life.
There are a number of caveats to the study. First, although all trial protocols gave some guidance on how to 
use the DSRS, it was not the primary outcome measure in any study and was largely done according to local prac-
tice. Hence, the DSRS scores, whilst prospectively collected, are potentially less accurate than could be achieved 
with formal training and this was reflected in the consensual validity exercise and respondents’ accompanying 
comments. In particular, there was less consensus for scoring patients on oral trials and liquid diets, as noted pre-
viously14. There was also less consensus on assigning supervision scores for patients on consistent amounts of oral 
trials, i.e. respondents found it easier to score supervision for patients either on full oral intake or limited trials. 
It is important that raters routinely using the DSRS clearly specify supervision level when making recommenda-
tions following the clinical bedside assessment. In the updated version of the DSRS (in Table 6), we provide rules 
for scoring supervision, including assigning diet, fluid and supervision scores for oral trials.
Second, the DSRS was devised and first used in 2010 and so antedates the 2017 IDDSI scale for determining 
levels of fluid thickness and modified food textures26. Further, DSRS measures different domains from IDDSI. 
Nevertheless, some comments by respondents in our assessment of content validity commented on the fact that 
the DSRS does not contain IDDSI terminology regarding wording and comprehensiveness. Going forward, we 
have proposed a redefinition of the DSRS to reflect IDDSI descriptors (Table 6) and plan to validate this updated 
scale in due course. Third, although the associations between DSRS and other radiological and clinical measures 
in the trials of Jayasekeran and Vasant5,8 were similar in magnitude to those seen in the STEPS trial, most were 
statistically non-significant due to their much smaller sample size and so reduced statistical power. This empha-
sises the importance of having large data sets when performing validation studies of clinical scales. Last, the 
distribution of DSRS will depend on the population of patients being studied and timing after stroke, and ceiling 
and floor effects are present at different times after stroke; for example in STEPS, one third of participants had a 
maximum score of 12 at baseline (reflecting the trial’s inclusion criteria) and a minimum score of zero 13 weeks 
later after natural resolution of dysphagia; this situation is analogous with other scales used in stroke, e.g. the 
Barthel Index28.
In summary, this study has shown that the 12-level DSRS is robust in terms of consensual, content, concur-
rent criterion and predictive criterion validity. Further, it shows “good-to-excellent” internal consistency, “excel-
lent” inter- and intra-rater reliability, is sensitive to natural and therapeutic change, and has a minimal clinically 
Figure 1. Histograms of distributions of Dysphagia Severity Rating Scale from STEPS trial. At baseline 
(n = 154), mean 7.6 (3.8), median 7.08, mode 12; at week 2 (n = 131), mean 4.9 (3.7), median 4.05, mode 3; at 
week 13 (n = 106) mean 2.7 (3.9), median 1.03, mode 0.
Score Fluids Score Diet Score Supervision
4 No oral fluids 4 Non oral feeding 4 No oral feeding
3 IDDSI level 4 - extremely thick 3 IDDSI level 4 - pureed or level  5 - minced & moist 3
Therapeutic feeding (SALT/trained 
staff)
2 IDDSI level 3 - moderately thick 2 IDDSI level 6 - soft & bite sized 2 Feeding by third party (untrained)
1 IDDSI level 1- slightly thick or level 2 - mildly thick 1 IDDSI level 7 - easy to chew 1 Eating with supervision
0 IDDSI level 0 - thin 0 IDDSI level 7 - regular 0 Eating independently
Table 6. Updated Dysphagia Severity Rating Scale incorporating International Dysphagia Diet Standardisation 
Initiative (IDDSI) levels25. DSRS supervision score 3 is always chosen when a patient is on limited or consistent 
oral trials and still requires NG/ PEG tube. Oral trials are scored from the fluid and diet subscales (i.e. 3 
onwards) and can be either trials of food or fluid or trials of food and fluids.
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important difference of 1 point. However, distribution of scores will depend on patient population and time 
post-onset. Specific guidance for accurate use of the DSRS is provided in the updated version, which includes 
corporation of the new IDDSI descriptors. Overall, our results suggest the DSRS is a valid tool for grading the 
severity of dysphagia in stroke; its ease of use make it relevant for use in clinical service delivery and clinical trials 
to define baseline dysphagia severity and assess the effect of natural history or therapeutic change.
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